Form 4: Faeth Therapeutics CEO Acquires Shares
Insider Transaction Report
Faeth Therapeutics, Inc. reports that President and CEO Anand Kiran Parikh acquired common stock through option exercises and purchases.
Summary
- Anand Kiran Parikh, President and CEO of Faeth Therapeutics, Inc., engaged in transactions involving the company's common stock on June 22, 2026.
- These transactions included the acquisition of 2,806 shares of common stock at a price of $19.76 per share.
- Additionally, 45,252 shares were acquired through the exercise of employee stock options at an exercise price of $1.16 per share.
- Another 8,213 shares were also acquired through employee stock options at an exercise price of $1.16 per share.
- Following these transactions, Mr. Parikh beneficially owns 817,699 shares of common stock.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as the CEO's stock acquisitions, especially through option exercises, can indicate confidence, but the lack of further context limits a stronger positive assessment.
Positives
- The CEO's acquisition of shares, particularly through option exercises at a lower price and direct purchase at a higher price, can signal confidence in the company's future prospects.
- The exercise of options at $1.16 and subsequent ownership indicates a belief in the stock's value exceeding this exercise price.
Negatives
- The filing does not provide context for the rationale behind these transactions, making it difficult to assess if they are routine or strategic.
Risks
- The filing does not explicitly mention any risks associated with these transactions.
Future Outlook
The filing does not contain forward-looking statements or guidance.
Industry Context
StockSavvy.ai notes that insider transactions, such as those reported by Faeth Therapeutics' CEO, are common in the biotechnology and pharmaceutical sectors as companies navigate development milestones and funding rounds. The exercise of options at a price significantly lower than a recent purchase price can be interpreted as a positive signal regarding management's valuation of the company's equity.
Stakeholder Impact
- Shareholders may view the CEO's stock purchases and option exercises as a positive signal of management's commitment and belief in the company's value.
- Employees with stock options may be encouraged by the CEO's actions, particularly if they also hold options.
Next Steps
- Continued monitoring of Anand Kiran Parikh's beneficial ownership and any future transactions.
Key Dates
| Date | Description |
|---|---|
| 08/01/2022 | Start date for vesting of shares subject to employee stock options in forty-eight successive equal monthly installments. |
| 06/16/2026 | Date of original Form 4/A filing which contained a clerical error regarding an expiration date. |
| 06/22/2026 | Date of transactions reported in the Form 4, including stock purchases and option exercises. |
| 06/24/2026 | Date of signature for the Form 4 filing. |
| 12/01/2035 | Corrected expiration date for an employee stock option. |
| 09/14/2032 | Expiration date for another employee stock option. |
| 03/01/2026 | Beginning date for monthly vesting of shares, continuing through January 1, 2027. |
| 02/01/2027 | Date when the balance of shares will fully vest. |
Keywords
Faeth Therapeutics, FTH, Form 4, Insider Trading, Stock Options, Common Stock, Anand Kiran Parikh, SEC Filing, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.